Clinical Trial Update: Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating anlotinib in combination with sintilimab as first-line therapy for advanced non Clear Cell Renal Cell Carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non Clear Cell Renal Carcinoma | Phase 2 | Status: UNKNOWN